Pharmaceutical organizations are under unprecedented pressure. Launches must move faster, customer expectations are rising, and data and AI are reshaping how decisions are made. Yet many life sciences companies still struggle with a familiar challenge: silos that slow execution and fragment the customer experience.

The issue is not that silos exist; many are essential for governance, compliance, and expertise. The challenge lies in how data, insights, and decisions flow across them. The organizations that will win in the next phase of commercial excellence are not dismantling silos but making them intentionally permeable—with the right data foundations, operating models, and technology enablers.

Moving beyond functional excellence and protecting guardrails

Historically, pharma has optimized functional excellence. Commercial, medical, digital, and regulatory teams each refined their own processes, KPIs, and systems. While this approach created deep expertise, it also introduced friction, especially at handover points where insights are lost or delayed.

From a customer perspective, these distinctions are invisible. Healthcare professionals and patients experience a brand through every interaction, across channels and roles. When those interactions feel disconnected, the result is confusion, inconsistency, and missed value.

Leading organizations are now shifting focus toward organizational excellence—aligning teams around shared outcomes rather than functional outputs. It is crucial to know that there are some silos that must remain intact. What are called “hard silos”—such as data, compliance, privacy and patient safety—cannot be compromised by teams. The real opportunity lies in addressing “soft silos”—behavioral and operational barriers that prevent insights from moving across teams, such as clinical-to-commercial transitions, medical and commercial collaboration in the field and market feedback loops that fail to reach decisions-makers. Organizations should focus on designing mechanisms that allow insights to flow consistently and compliantly between different teams. But mechanisms alone are not enough—without the right operating model, they remain isolated initiatives rather than enterprise capabilities.

Rethinking Next-Best-Action and the power of AI

How do organizations operationalize insight flow at scale? Technology alone does not solve fragmentation. Transformation starts with the operating model. Modern commercial operating models clarify:

• How functions contribute to shared customer outcomes
• How success is measured across teams
• How global capabilities scale with local flexibility
• How data enables connected decision-making

A strong example is the evolution of the next best action concept. What was once a sales optimization tool has become an enterprise capability, designed to orchestrate the most relevant interaction across personal, digital, and hybrid channels. It should be used for all customer profiles and roles. When built around the customer rather than the function, it becomes a powerful driver of omnichannel execution.

IQVIA Commercial Solutions increasingly supports this shift by bringing together data, analytics, and orchestration across the commercial ecosystem, enabling organizations to act with speed and confidence. Thanks to AI, it has the potential to improve commercial effectiveness. When implemented within individual functions, AI can reinforce silos rather than remove them. To unlock value, AI must be embedded into end-to-end commercial workflows, supported by unified data foundation, governed at the enterprise level and aligned to shared business outcomes.

High-impact use cases already emerging across the industry include:

• Medical–legal–regulatory review optimization
• Insight generation across customer touchpoints
• Campaign and content orchestration
• Field enablement through intelligent assistants

Used correctly, AI accelerates insight-to-action cycles and improves consistency across customer engagement.

Culture, incentives, and human alignment

Technology is only part of the equation. Behind every silo sits human behavior: what people are measured on, how decisions are made, and whether teams are incentivized to act beyond their functional boundaries. When incentives remain tied to narrow functional success, silos persist even in organizations that appear structurally aligned.

That is why organizations that move faster focus not only on operating models and data, but also on incentives, accountability, and culture. They align KPIs around shared outcomes such as customer experience and patient impact, establish clear decision rights for cross-functional priorities, and treat governance as a way to enable faster, coordinated action across teams.

Culture is the critical enabler. Organizations need people who are willing to experiment, and open to changing how work gets done. In that sense, adoption is not the starting point but the result of a culture that supports curiosity, collaboration, and continuous adaptation.

The customer and patient journey as the North Star

One of the most effective ways to align across functions is to anchor the organization around a shared North Star: the customer and patient journey.

While no single function owns the journey from end-to-end, every function contributes. When teams identify and align on where customers experience friction—whether in awareness, initiation, adherence, or ongoing engagement— they can collaborate more effectively to deliver real-world impact.

This shift also reframes success from activity-based metrics to outcomes such as experience quality, relevance of engagement, and sustainable patient impact. These are all factors that influence how customers perceive value and, ultimately, the value delivered to the patients.

Commercial leaders increasingly recognize that customer-centricity is not a channel strategy—it is an operating model decision.

The path forward for pharma commercial leaders

Breaking silos in pharma does not mean breaking compliance, governance, or functional expertise. It means designing the flow—of insights, decisions, and actions—across the commercial organization.

The most successful commercial teams will be those that:

• Modernize their operating models
• Use data and AI as enterprise enablers, not functional tools
• Balance global scale with local execution
• Build cultures that value collaboration and adaptability
• Align around the customer and patient journey

For pharma and life sciences leaders, this is not a technology challenge alone. It is a commercial strategy imperative.